nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—CYP3A4—Fingolimod—multiple sclerosis	0.112	0.223	CbGbCtD
Glipizide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0721	0.144	CbGbCtD
Glipizide—CYP3A4—Triamcinolone—multiple sclerosis	0.0547	0.109	CbGbCtD
Glipizide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0526	0.105	CbGbCtD
Glipizide—CYP2C9—Dexamethasone—multiple sclerosis	0.0469	0.0934	CbGbCtD
Glipizide—CYP3A4—Betamethasone—multiple sclerosis	0.0469	0.0934	CbGbCtD
Glipizide—CYP3A4—Prednisolone—multiple sclerosis	0.0463	0.0921	CbGbCtD
Glipizide—CYP3A4—Prednisone—multiple sclerosis	0.0437	0.087	CbGbCtD
Glipizide—CYP3A4—Dexamethasone—multiple sclerosis	0.0273	0.0543	CbGbCtD
Glipizide—PPARG—leg—multiple sclerosis	0.00775	0.28	CbGeAlD
Glipizide—Chlorpropamide—SLC15A2—multiple sclerosis	0.00498	0.325	CrCbGaD
Glipizide—Tolbutamide—SLC15A2—multiple sclerosis	0.00486	0.317	CrCbGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTPRK—multiple sclerosis	0.00408	0.052	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00358	0.0456	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00358	0.0456	CbGpPWpGaD
Glipizide—Glyburide—SLC15A2—multiple sclerosis	0.00337	0.22	CrCbGaD
Glipizide—ABCC8—Potassium Channels—KCNA3—multiple sclerosis	0.00329	0.042	CbGpPWpGaD
Glipizide—KCNJ11—Potassium Channels—KCNA3—multiple sclerosis	0.00319	0.0407	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TBX21—multiple sclerosis	0.00263	0.0335	CbGpPWpGaD
Glipizide—ABCC8—brainstem—multiple sclerosis	0.00237	0.0856	CbGeAlD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—multiple sclerosis	0.00193	0.0246	CbGpPWpGaD
Glipizide—ABCC8—medulla oblongata—multiple sclerosis	0.00165	0.0597	CbGeAlD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	0.00156	0.0199	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors—PGR—multiple sclerosis	0.00153	0.0195	CbGpPWpGaD
Glipizide—ABCC8—midbrain—multiple sclerosis	0.00151	0.0546	CbGeAlD
Glipizide—ABCC8—spinal cord—multiple sclerosis	0.00147	0.0532	CbGeAlD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—multiple sclerosis	0.00145	0.0185	CbGpPWpGaD
Glipizide—ABCC8—Neuronal System—KCNA3—multiple sclerosis	0.00144	0.0183	CbGpPWpGaD
Glipizide—KCNJ11—Neuronal System—KCNA3—multiple sclerosis	0.00139	0.0178	CbGpPWpGaD
Glipizide—Gliclazide—ALB—multiple sclerosis	0.00138	0.0901	CrCbGaD
Glipizide—KCNJ11—nervous system—multiple sclerosis	0.00135	0.0487	CbGeAlD
Glipizide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00132	0.0168	CbGpPWpGaD
Glipizide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00132	0.0168	CbGpPWpGaD
Glipizide—KCNJ11—central nervous system—multiple sclerosis	0.0013	0.0469	CbGeAlD
Glipizide—KCNJ11—cerebellum—multiple sclerosis	0.00127	0.0458	CbGeAlD
Glipizide—ABCC8—nervous system—multiple sclerosis	0.00124	0.0448	CbGeAlD
Glipizide—PPARG—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00121	0.0154	CbGpPWpGaD
Glipizide—ABCC8—central nervous system—multiple sclerosis	0.00119	0.0432	CbGeAlD
Glipizide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00117	0.0149	CbGpPWpGaD
Glipizide—ABCC8—cerebellum—multiple sclerosis	0.00117	0.0422	CbGeAlD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	0.00108	0.0137	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors—VDR—multiple sclerosis	0.00107	0.0137	CbGpPWpGaD
Glipizide—KCNJ11—brain—multiple sclerosis	0.00103	0.0372	CbGeAlD
Glipizide—ABCC8—brain—multiple sclerosis	0.000948	0.0343	CbGeAlD
Glipizide—PPARG—nervous system—multiple sclerosis	0.000947	0.0342	CbGeAlD
Glipizide—PPARG—central nervous system—multiple sclerosis	0.000912	0.033	CbGeAlD
Glipizide—KCNJ11—Type II diabetes mellitus—MAPK1—multiple sclerosis	0.000872	0.0111	CbGpPWpGaD
Glipizide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000869	0.0111	CbGpPWpGaD
Glipizide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000869	0.0111	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.000846	0.0108	CbGpPWpGaD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000836	0.0107	CbGpPWpGaD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000836	0.0107	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	0.000836	0.0107	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—TNFRSF1A—multiple sclerosis	0.000834	0.0106	CbGpPWpGaD
Glipizide—ABCC8—FOXA2 and FOXA3 transcription factor networks—ALB—multiple sclerosis	0.000833	0.0106	CbGpPWpGaD
Glipizide—KCNJ11—Type II diabetes mellitus—TNF—multiple sclerosis	0.000831	0.0106	CbGpPWpGaD
Glipizide—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000825	0.0105	CbGpPWpGaD
Glipizide—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000825	0.0105	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	0.000814	0.0104	CbGpPWpGaD
Glipizide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—ALB—multiple sclerosis	0.000808	0.0103	CbGpPWpGaD
Glipizide—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000769	0.00981	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	0.000745	0.0095	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—CD24—multiple sclerosis	0.000732	0.00933	CbGpPWpGaD
Glipizide—Diarrhoea—Azathioprine—multiple sclerosis	0.000726	0.00193	CcSEcCtD
Glipizide—Discomfort—Prednisolone—multiple sclerosis	0.000725	0.00193	CcSEcCtD
Glipizide—Glyburide—ALB—multiple sclerosis	0.000724	0.0473	CrCbGaD
Glipizide—PPARG—brain—multiple sclerosis	0.000724	0.0262	CbGeAlD
Glipizide—Abdominal discomfort—Methotrexate—multiple sclerosis	0.00072	0.00191	CcSEcCtD
Glipizide—Erythema—Betamethasone—multiple sclerosis	0.000719	0.00191	CcSEcCtD
Glipizide—Erythema—Dexamethasone—multiple sclerosis	0.000719	0.00191	CcSEcCtD
Glipizide—Malaise—Triamcinolone—multiple sclerosis	0.000715	0.0019	CcSEcCtD
Glipizide—Pancytopenia—Methotrexate—multiple sclerosis	0.000713	0.0019	CcSEcCtD
Glipizide—Malaise—Methylprednisolone—multiple sclerosis	0.000713	0.0019	CcSEcCtD
Glipizide—Vertigo—Triamcinolone—multiple sclerosis	0.000712	0.00189	CcSEcCtD
Glipizide—Syncope—Triamcinolone—multiple sclerosis	0.000711	0.00189	CcSEcCtD
Glipizide—Vertigo—Methylprednisolone—multiple sclerosis	0.000711	0.00189	CcSEcCtD
Glipizide—Syncope—Methylprednisolone—multiple sclerosis	0.000709	0.00189	CcSEcCtD
Glipizide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000707	0.00188	CcSEcCtD
Glipizide—Oedema—Prednisolone—multiple sclerosis	0.000703	0.00187	CcSEcCtD
Glipizide—Dysuria—Methotrexate—multiple sclerosis	0.000702	0.00187	CcSEcCtD
Glipizide—Dizziness—Azathioprine—multiple sclerosis	0.000701	0.00186	CcSEcCtD
Glipizide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000701	0.00186	CcSEcCtD
Glipizide—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000697	0.00185	CcSEcCtD
Glipizide—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000695	0.00185	CcSEcCtD
Glipizide—PPARG—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000693	0.00884	CbGpPWpGaD
Glipizide—Shock—Prednisolone—multiple sclerosis	0.000692	0.00184	CcSEcCtD
Glipizide—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000686	0.00182	CcSEcCtD
Glipizide—Hypertension—Triamcinolone—multiple sclerosis	0.000684	0.00182	CcSEcCtD
Glipizide—Hypertension—Methylprednisolone—multiple sclerosis	0.000683	0.00182	CcSEcCtD
Glipizide—Urticaria—Mitoxantrone—multiple sclerosis	0.000681	0.00181	CcSEcCtD
Glipizide—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00068	0.00181	CcSEcCtD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000678	0.00864	CbGpPWpGaD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000678	0.00864	CbGpPWpGaD
Glipizide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000678	0.0018	CcSEcCtD
Glipizide—Myalgia—Triamcinolone—multiple sclerosis	0.000675	0.00179	CcSEcCtD
Glipizide—Vomiting—Azathioprine—multiple sclerosis	0.000674	0.00179	CcSEcCtD
Glipizide—Myalgia—Methylprednisolone—multiple sclerosis	0.000673	0.00179	CcSEcCtD
Glipizide—Arthralgia—Methylprednisolone—multiple sclerosis	0.000673	0.00179	CcSEcCtD
Glipizide—Eye disorder—Prednisone—multiple sclerosis	0.000672	0.00179	CcSEcCtD
Glipizide—Anxiety—Methylprednisolone—multiple sclerosis	0.000671	0.00178	CcSEcCtD
Glipizide—Drowsiness—Methotrexate—multiple sclerosis	0.00067	0.00178	CcSEcCtD
Glipizide—Rash—Azathioprine—multiple sclerosis	0.000669	0.00178	CcSEcCtD
Glipizide—Dermatitis—Azathioprine—multiple sclerosis	0.000668	0.00178	CcSEcCtD
Glipizide—Flushing—Prednisone—multiple sclerosis	0.000668	0.00178	CcSEcCtD
Glipizide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000667	0.00177	CcSEcCtD
Glipizide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000667	0.00177	CcSEcCtD
Glipizide—Discomfort—Triamcinolone—multiple sclerosis	0.000667	0.00177	CcSEcCtD
Glipizide—Discomfort—Methylprednisolone—multiple sclerosis	0.000665	0.00177	CcSEcCtD
Glipizide—Headache—Azathioprine—multiple sclerosis	0.000664	0.00177	CcSEcCtD
Glipizide—Conjunctivitis—Methotrexate—multiple sclerosis	0.000651	0.00173	CcSEcCtD
Glipizide—Confusional state—Methylprednisolone—multiple sclerosis	0.000651	0.00173	CcSEcCtD
Glipizide—Malaise—Dexamethasone—multiple sclerosis	0.000649	0.00172	CcSEcCtD
Glipizide—Malaise—Betamethasone—multiple sclerosis	0.000649	0.00172	CcSEcCtD
Glipizide—Oedema—Triamcinolone—multiple sclerosis	0.000647	0.00172	CcSEcCtD
Glipizide—Vertigo—Dexamethasone—multiple sclerosis	0.000646	0.00172	CcSEcCtD
Glipizide—Vertigo—Betamethasone—multiple sclerosis	0.000646	0.00172	CcSEcCtD
Glipizide—Syncope—Betamethasone—multiple sclerosis	0.000645	0.00171	CcSEcCtD
Glipizide—Syncope—Dexamethasone—multiple sclerosis	0.000645	0.00171	CcSEcCtD
Glipizide—Arrhythmia—Prednisone—multiple sclerosis	0.000643	0.00171	CcSEcCtD
Glipizide—Sweating—Methotrexate—multiple sclerosis	0.000642	0.00171	CcSEcCtD
Glipizide—Shock—Triamcinolone—multiple sclerosis	0.000636	0.00169	CcSEcCtD
Glipizide—Insomnia—Prednisolone—multiple sclerosis	0.000636	0.00169	CcSEcCtD
Glipizide—Shock—Methylprednisolone—multiple sclerosis	0.000635	0.00169	CcSEcCtD
Glipizide—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000633	0.00168	CcSEcCtD
Glipizide—Loss of consciousness—Betamethasone—multiple sclerosis	0.000632	0.00168	CcSEcCtD
Glipizide—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000632	0.00168	CcSEcCtD
Glipizide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000632	0.00168	CcSEcCtD
Glipizide—Paraesthesia—Prednisolone—multiple sclerosis	0.000632	0.00168	CcSEcCtD
Glipizide—Nausea—Azathioprine—multiple sclerosis	0.00063	0.00167	CcSEcCtD
Glipizide—Erythema—Prednisone—multiple sclerosis	0.000626	0.00166	CcSEcCtD
Glipizide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000625	0.00166	CcSEcCtD
Glipizide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000625	0.00166	CcSEcCtD
Glipizide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000624	0.00166	CcSEcCtD
Glipizide—Hypertension—Dexamethasone—multiple sclerosis	0.000621	0.00165	CcSEcCtD
Glipizide—Hypertension—Betamethasone—multiple sclerosis	0.000621	0.00165	CcSEcCtD
Glipizide—Asthenia—Mitoxantrone—multiple sclerosis	0.000615	0.00164	CcSEcCtD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—TNF—multiple sclerosis	0.000614	0.00783	CbGpPWpGaD
Glipizide—Myalgia—Dexamethasone—multiple sclerosis	0.000612	0.00163	CcSEcCtD
Glipizide—Myalgia—Betamethasone—multiple sclerosis	0.000612	0.00163	CcSEcCtD
Glipizide—Anxiety—Betamethasone—multiple sclerosis	0.00061	0.00162	CcSEcCtD
Glipizide—Anxiety—Dexamethasone—multiple sclerosis	0.00061	0.00162	CcSEcCtD
Glipizide—Discomfort—Dexamethasone—multiple sclerosis	0.000605	0.00161	CcSEcCtD
Glipizide—Discomfort—Betamethasone—multiple sclerosis	0.000605	0.00161	CcSEcCtD
Glipizide—Pain—Prednisolone—multiple sclerosis	0.000602	0.0016	CcSEcCtD
Glipizide—Hepatitis—Methotrexate—multiple sclerosis	0.000601	0.0016	CcSEcCtD
Glipizide—Pharyngitis—Methotrexate—multiple sclerosis	0.000597	0.00159	CcSEcCtD
Glipizide—Vision blurred—Prednisone—multiple sclerosis	0.00059	0.00157	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000589	0.00157	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000588	0.00156	CcSEcCtD
Glipizide—Oedema—Dexamethasone—multiple sclerosis	0.000587	0.00156	CcSEcCtD
Glipizide—Oedema—Betamethasone—multiple sclerosis	0.000587	0.00156	CcSEcCtD
Glipizide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000587	0.00156	CcSEcCtD
Glipizide—Insomnia—Triamcinolone—multiple sclerosis	0.000585	0.00156	CcSEcCtD
Glipizide—Insomnia—Methylprednisolone—multiple sclerosis	0.000584	0.00155	CcSEcCtD
Glipizide—Ill-defined disorder—Prednisone—multiple sclerosis	0.000581	0.00154	CcSEcCtD
Glipizide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000581	0.00154	CcSEcCtD
Glipizide—Feeling abnormal—Prednisolone—multiple sclerosis	0.00058	0.00154	CcSEcCtD
Glipizide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00058	0.00154	CcSEcCtD
Glipizide—Visual impairment—Methotrexate—multiple sclerosis	0.000579	0.00154	CcSEcCtD
Glipizide—Shock—Betamethasone—multiple sclerosis	0.000577	0.00154	CcSEcCtD
Glipizide—Shock—Dexamethasone—multiple sclerosis	0.000577	0.00154	CcSEcCtD
Glipizide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000577	0.00153	CcSEcCtD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.000575	0.00733	CbGpPWpGaD
Glipizide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000575	0.00153	CcSEcCtD
Glipizide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000575	0.00153	CcSEcCtD
Glipizide—Dyspepsia—Triamcinolone—multiple sclerosis	0.000569	0.00151	CcSEcCtD
Glipizide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000568	0.00151	CcSEcCtD
Glipizide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000567	0.00151	CcSEcCtD
Glipizide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000567	0.00151	CcSEcCtD
Glipizide—Malaise—Prednisone—multiple sclerosis	0.000565	0.0015	CcSEcCtD
Glipizide—Vertigo—Prednisone—multiple sclerosis	0.000563	0.0015	CcSEcCtD
Glipizide—Eye disorder—Methotrexate—multiple sclerosis	0.000562	0.00149	CcSEcCtD
Glipizide—Syncope—Prednisone—multiple sclerosis	0.000562	0.00149	CcSEcCtD
Glipizide—Anorexia—Dexamethasone—multiple sclerosis	0.000559	0.00149	CcSEcCtD
Glipizide—Anorexia—Betamethasone—multiple sclerosis	0.000559	0.00149	CcSEcCtD
Glipizide—Urticaria—Prednisolone—multiple sclerosis	0.000559	0.00149	CcSEcCtD
Glipizide—Pain—Triamcinolone—multiple sclerosis	0.000553	0.00147	CcSEcCtD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000552	0.00703	CbGpPWpGaD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000552	0.00703	CbGpPWpGaD
Glipizide—Loss of consciousness—Prednisone—multiple sclerosis	0.00055	0.00146	CcSEcCtD
Glipizide—Vomiting—Mitoxantrone—multiple sclerosis	0.000545	0.00145	CcSEcCtD
Glipizide—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000544	0.00694	CbGpPWpGaD
Glipizide—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000544	0.00694	CbGpPWpGaD
Glipizide—Hypertension—Prednisone—multiple sclerosis	0.000541	0.00144	CcSEcCtD
Glipizide—Rash—Mitoxantrone—multiple sclerosis	0.000541	0.00144	CcSEcCtD
Glipizide—Dermatitis—Mitoxantrone—multiple sclerosis	0.00054	0.00144	CcSEcCtD
Glipizide—Chills—Methotrexate—multiple sclerosis	0.00054	0.00143	CcSEcCtD
Glipizide—Headache—Mitoxantrone—multiple sclerosis	0.000537	0.00143	CcSEcCtD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.000537	0.00685	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000536	0.00683	CbGpPWpGaD
Glipizide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000535	0.00142	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000535	0.00142	CcSEcCtD
Glipizide—Arthralgia—Prednisone—multiple sclerosis	0.000533	0.00142	CcSEcCtD
Glipizide—Myalgia—Prednisone—multiple sclerosis	0.000533	0.00142	CcSEcCtD
Glipizide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000533	0.00142	CcSEcCtD
Glipizide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000532	0.00141	CcSEcCtD
Glipizide—Anxiety—Prednisone—multiple sclerosis	0.000531	0.00141	CcSEcCtD
Glipizide—Insomnia—Dexamethasone—multiple sclerosis	0.000531	0.00141	CcSEcCtD
Glipizide—Insomnia—Betamethasone—multiple sclerosis	0.000531	0.00141	CcSEcCtD
Glipizide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000528	0.0014	CcSEcCtD
Glipizide—Paraesthesia—Betamethasone—multiple sclerosis	0.000527	0.0014	CcSEcCtD
Glipizide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000527	0.0014	CcSEcCtD
Glipizide—Discomfort—Prednisone—multiple sclerosis	0.000527	0.0014	CcSEcCtD
Glipizide—Erythema—Methotrexate—multiple sclerosis	0.000523	0.00139	CcSEcCtD
Glipizide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000518	0.00138	CcSEcCtD
Glipizide—Dyspepsia—Dexamethasone—multiple sclerosis	0.000517	0.00137	CcSEcCtD
Glipizide—Dyspepsia—Betamethasone—multiple sclerosis	0.000517	0.00137	CcSEcCtD
Glipizide—Urticaria—Triamcinolone—multiple sclerosis	0.000514	0.00137	CcSEcCtD
Glipizide—Urticaria—Methylprednisolone—multiple sclerosis	0.000513	0.00136	CcSEcCtD
Glipizide—Oedema—Prednisone—multiple sclerosis	0.000511	0.00136	CcSEcCtD
Glipizide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00051	0.00136	CcSEcCtD
Glipizide—Decreased appetite—Betamethasone—multiple sclerosis	0.00051	0.00136	CcSEcCtD
Glipizide—Decreased appetite—Dexamethasone—multiple sclerosis	0.00051	0.00136	CcSEcCtD
Glipizide—Nausea—Mitoxantrone—multiple sclerosis	0.000509	0.00135	CcSEcCtD
Glipizide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000507	0.00135	CcSEcCtD
Glipizide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000507	0.00135	CcSEcCtD
Glipizide—Shock—Prednisone—multiple sclerosis	0.000503	0.00134	CcSEcCtD
Glipizide—Pain—Dexamethasone—multiple sclerosis	0.000502	0.00133	CcSEcCtD
Glipizide—Pain—Betamethasone—multiple sclerosis	0.000502	0.00133	CcSEcCtD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—IL6—multiple sclerosis	0.000495	0.00632	CbGpPWpGaD
Glipizide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000495	0.00631	CbGpPWpGaD
Glipizide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000494	0.00131	CcSEcCtD
Glipizide—Vision blurred—Methotrexate—multiple sclerosis	0.000493	0.00131	CcSEcCtD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	0.000492	0.00627	CbGpPWpGaD
Glipizide—Anorexia—Prednisone—multiple sclerosis	0.000487	0.0013	CcSEcCtD
Glipizide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000486	0.00129	CcSEcCtD
Glipizide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000484	0.00129	CcSEcCtD
Glipizide—Feeling abnormal—Betamethasone—multiple sclerosis	0.000484	0.00129	CcSEcCtD
Glipizide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00048	0.00128	CcSEcCtD
Glipizide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00048	0.00128	CcSEcCtD
Glipizide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000477	0.00127	CcSEcCtD
Glipizide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000476	0.00126	CcSEcCtD
Glipizide—Malaise—Methotrexate—multiple sclerosis	0.000472	0.00125	CcSEcCtD
Glipizide—Vertigo—Methotrexate—multiple sclerosis	0.00047	0.00125	CcSEcCtD
Glipizide—Leukopenia—Methotrexate—multiple sclerosis	0.000469	0.00125	CcSEcCtD
Glipizide—Urticaria—Dexamethasone—multiple sclerosis	0.000466	0.00124	CcSEcCtD
Glipizide—Urticaria—Betamethasone—multiple sclerosis	0.000466	0.00124	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000466	0.00124	CcSEcCtD
Glipizide—Dizziness—Prednisolone—multiple sclerosis	0.000465	0.00124	CcSEcCtD
Glipizide—Asthenia—Triamcinolone—multiple sclerosis	0.000464	0.00123	CcSEcCtD
Glipizide—Abdominal pain—Betamethasone—multiple sclerosis	0.000464	0.00123	CcSEcCtD
Glipizide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000464	0.00123	CcSEcCtD
Glipizide—Asthenia—Methylprednisolone—multiple sclerosis	0.000463	0.00123	CcSEcCtD
Glipizide—Insomnia—Prednisone—multiple sclerosis	0.000462	0.00123	CcSEcCtD
Glipizide—Paraesthesia—Prednisone—multiple sclerosis	0.000459	0.00122	CcSEcCtD
Glipizide—Pruritus—Triamcinolone—multiple sclerosis	0.000458	0.00122	CcSEcCtD
Glipizide—Pruritus—Methylprednisolone—multiple sclerosis	0.000457	0.00121	CcSEcCtD
Glipizide—Dyspepsia—Prednisone—multiple sclerosis	0.00045	0.0012	CcSEcCtD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000447	0.0057	CbGpPWpGaD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000447	0.0057	CbGpPWpGaD
Glipizide—Arthralgia—Methotrexate—multiple sclerosis	0.000446	0.00118	CcSEcCtD
Glipizide—Myalgia—Methotrexate—multiple sclerosis	0.000446	0.00118	CcSEcCtD
Glipizide—Decreased appetite—Prednisone—multiple sclerosis	0.000444	0.00118	CcSEcCtD
Glipizide—Rash—Prednisolone—multiple sclerosis	0.000444	0.00118	CcSEcCtD
Glipizide—Dermatitis—Prednisolone—multiple sclerosis	0.000443	0.00118	CcSEcCtD
Glipizide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000442	0.00117	CcSEcCtD
Glipizide—Headache—Prednisolone—multiple sclerosis	0.000441	0.00117	CcSEcCtD
Glipizide—Discomfort—Methotrexate—multiple sclerosis	0.00044	0.00117	CcSEcCtD
Glipizide—Constipation—Prednisone—multiple sclerosis	0.000437	0.00116	CcSEcCtD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	0.000437	0.00557	CbGpPWpGaD
Glipizide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000431	0.0055	CbGpPWpGaD
Glipizide—Confusional state—Methotrexate—multiple sclerosis	0.000431	0.00115	CcSEcCtD
Glipizide—Dizziness—Triamcinolone—multiple sclerosis	0.000428	0.00114	CcSEcCtD
Glipizide—Dizziness—Methylprednisolone—multiple sclerosis	0.000427	0.00113	CcSEcCtD
Glipizide—CYP3A4—nervous system—multiple sclerosis	0.000423	0.0153	CbGeAlD
Glipizide—Feeling abnormal—Prednisone—multiple sclerosis	0.000421	0.00112	CcSEcCtD
Glipizide—Asthenia—Betamethasone—multiple sclerosis	0.000421	0.00112	CcSEcCtD
Glipizide—Asthenia—Dexamethasone—multiple sclerosis	0.000421	0.00112	CcSEcCtD
Glipizide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000418	0.00111	CcSEcCtD
Glipizide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000418	0.00111	CcSEcCtD
Glipizide—Nausea—Prednisolone—multiple sclerosis	0.000418	0.00111	CcSEcCtD
Glipizide—Pruritus—Betamethasone—multiple sclerosis	0.000415	0.0011	CcSEcCtD
Glipizide—Pruritus—Dexamethasone—multiple sclerosis	0.000415	0.0011	CcSEcCtD
Glipizide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000413	0.0011	CcSEcCtD
Glipizide—Vomiting—Triamcinolone—multiple sclerosis	0.000411	0.00109	CcSEcCtD
Glipizide—Vomiting—Methylprednisolone—multiple sclerosis	0.00041	0.00109	CcSEcCtD
Glipizide—Rash—Triamcinolone—multiple sclerosis	0.000408	0.00108	CcSEcCtD
Glipizide—Dermatitis—Triamcinolone—multiple sclerosis	0.000407	0.00108	CcSEcCtD
Glipizide—Anorexia—Methotrexate—multiple sclerosis	0.000407	0.00108	CcSEcCtD
Glipizide—CYP3A4—central nervous system—multiple sclerosis	0.000407	0.0147	CbGeAlD
Glipizide—Rash—Methylprednisolone—multiple sclerosis	0.000407	0.00108	CcSEcCtD
Glipizide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000407	0.00108	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000406	0.00518	CbGpPWpGaD
Glipizide—Urticaria—Prednisone—multiple sclerosis	0.000406	0.00108	CcSEcCtD
Glipizide—Headache—Triamcinolone—multiple sclerosis	0.000405	0.00108	CcSEcCtD
Glipizide—Headache—Methylprednisolone—multiple sclerosis	0.000404	0.00107	CcSEcCtD
Glipizide—Abdominal pain—Prednisone—multiple sclerosis	0.000404	0.00107	CcSEcCtD
Glipizide—ABCC8—Neuronal System—BCHE—multiple sclerosis	0.000403	0.00514	CbGpPWpGaD
Glipizide—Diarrhoea—Betamethasone—multiple sclerosis	0.000402	0.00107	CcSEcCtD
Glipizide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000402	0.00107	CcSEcCtD
Glipizide—KCNJ11—Neuronal System—BCHE—multiple sclerosis	0.000391	0.00499	CbGpPWpGaD
Glipizide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000389	0.00103	CcSEcCtD
Glipizide—Dizziness—Betamethasone—multiple sclerosis	0.000388	0.00103	CcSEcCtD
Glipizide—Dizziness—Dexamethasone—multiple sclerosis	0.000388	0.00103	CcSEcCtD
Glipizide—Insomnia—Methotrexate—multiple sclerosis	0.000386	0.00103	CcSEcCtD
Glipizide—Nausea—Triamcinolone—multiple sclerosis	0.000384	0.00102	CcSEcCtD
Glipizide—Paraesthesia—Methotrexate—multiple sclerosis	0.000384	0.00102	CcSEcCtD
Glipizide—Nausea—Methylprednisolone—multiple sclerosis	0.000383	0.00102	CcSEcCtD
Glipizide—Dyspnoea—Methotrexate—multiple sclerosis	0.000381	0.00101	CcSEcCtD
Glipizide—Somnolence—Methotrexate—multiple sclerosis	0.00038	0.00101	CcSEcCtD
Glipizide—Hypersensitivity—Prednisone—multiple sclerosis	0.000377	0.001	CcSEcCtD
Glipizide—Dyspepsia—Methotrexate—multiple sclerosis	0.000376	0.001	CcSEcCtD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000376	0.00479	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000376	0.00479	CbGpPWpGaD
Glipizide—Vomiting—Betamethasone—multiple sclerosis	0.000373	0.000992	CcSEcCtD
Glipizide—Vomiting—Dexamethasone—multiple sclerosis	0.000373	0.000992	CcSEcCtD
Glipizide—Decreased appetite—Methotrexate—multiple sclerosis	0.000371	0.000987	CcSEcCtD
Glipizide—Rash—Betamethasone—multiple sclerosis	0.00037	0.000984	CcSEcCtD
Glipizide—Rash—Dexamethasone—multiple sclerosis	0.00037	0.000984	CcSEcCtD
Glipizide—Dermatitis—Betamethasone—multiple sclerosis	0.00037	0.000983	CcSEcCtD
Glipizide—Dermatitis—Dexamethasone—multiple sclerosis	0.00037	0.000983	CcSEcCtD
Glipizide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000369	0.00098	CcSEcCtD
Glipizide—Headache—Betamethasone—multiple sclerosis	0.000368	0.000977	CcSEcCtD
Glipizide—Headache—Dexamethasone—multiple sclerosis	0.000368	0.000977	CcSEcCtD
Glipizide—Asthenia—Prednisone—multiple sclerosis	0.000367	0.000975	CcSEcCtD
Glipizide—Pain—Methotrexate—multiple sclerosis	0.000365	0.000971	CcSEcCtD
Glipizide—Pruritus—Prednisone—multiple sclerosis	0.000362	0.000961	CcSEcCtD
Glipizide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.00036	0.00459	CbGpPWpGaD
Glipizide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.00036	0.00459	CbGpPWpGaD
Glipizide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000355	0.00453	CbGpPWpGaD
Glipizide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000355	0.00453	CbGpPWpGaD
Glipizide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000352	0.000936	CcSEcCtD
Glipizide—Diarrhoea—Prednisone—multiple sclerosis	0.00035	0.00093	CcSEcCtD
Glipizide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000349	0.000929	CcSEcCtD
Glipizide—PPARG—Adipogenesis—FAS—multiple sclerosis	0.000349	0.00445	CbGpPWpGaD
Glipizide—Nausea—Betamethasone—multiple sclerosis	0.000349	0.000927	CcSEcCtD
Glipizide—Nausea—Dexamethasone—multiple sclerosis	0.000349	0.000927	CcSEcCtD
Glipizide—Urticaria—Methotrexate—multiple sclerosis	0.000339	0.000902	CcSEcCtD
Glipizide—Dizziness—Prednisone—multiple sclerosis	0.000338	0.000899	CcSEcCtD
Glipizide—Abdominal pain—Methotrexate—multiple sclerosis	0.000338	0.000898	CcSEcCtD
Glipizide—PPARG—Gene Expression—ZNF746—multiple sclerosis	0.000334	0.00426	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—SRM—multiple sclerosis	0.000331	0.00422	CbGpPWpGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—MYC—multiple sclerosis	0.000331	0.00422	CbGpPWpGaD
Glipizide—Vomiting—Prednisone—multiple sclerosis	0.000325	0.000864	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—MAPK1—multiple sclerosis	0.000324	0.00413	CbGpPWpGaD
Glipizide—Rash—Prednisone—multiple sclerosis	0.000322	0.000857	CcSEcCtD
Glipizide—Dermatitis—Prednisone—multiple sclerosis	0.000322	0.000856	CcSEcCtD
Glipizide—KCNJ11—Metabolism—SRM—multiple sclerosis	0.000321	0.0041	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000321	0.00409	CbGpPWpGaD
Glipizide—Headache—Prednisone—multiple sclerosis	0.00032	0.000851	CcSEcCtD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	0.000318	0.00406	CbGpPWpGaD
Glipizide—Hypersensitivity—Methotrexate—multiple sclerosis	0.000315	0.000837	CcSEcCtD
Glipizide—Asthenia—Methotrexate—multiple sclerosis	0.000306	0.000815	CcSEcCtD
Glipizide—PPARG—Gene Expression—PTBP1—multiple sclerosis	0.000305	0.00389	CbGpPWpGaD
Glipizide—Nausea—Prednisone—multiple sclerosis	0.000304	0.000807	CcSEcCtD
Glipizide—Pruritus—Methotrexate—multiple sclerosis	0.000302	0.000803	CcSEcCtD
Glipizide—Diarrhoea—Methotrexate—multiple sclerosis	0.000292	0.000777	CcSEcCtD
Glipizide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000284	0.00362	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000284	0.00362	CbGpPWpGaD
Glipizide—Dizziness—Methotrexate—multiple sclerosis	0.000282	0.000751	CcSEcCtD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—STAT3—multiple sclerosis	0.000281	0.00358	CbGpPWpGaD
Glipizide—Vomiting—Methotrexate—multiple sclerosis	0.000272	0.000722	CcSEcCtD
Glipizide—Rash—Methotrexate—multiple sclerosis	0.000269	0.000716	CcSEcCtD
Glipizide—Dermatitis—Methotrexate—multiple sclerosis	0.000269	0.000715	CcSEcCtD
Glipizide—Headache—Methotrexate—multiple sclerosis	0.000268	0.000711	CcSEcCtD
Glipizide—Nausea—Methotrexate—multiple sclerosis	0.000254	0.000675	CcSEcCtD
Glipizide—PPARG—Circadian rythm related genes—FAS—multiple sclerosis	0.000246	0.00314	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—TNF—multiple sclerosis	0.000243	0.0031	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—PRNP—multiple sclerosis	0.000242	0.00308	CbGpPWpGaD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—TGFB1—multiple sclerosis	0.000241	0.00308	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000238	0.00303	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000238	0.00303	CbGpPWpGaD
Glipizide—PPARG—Metabolism—SRM—multiple sclerosis	0.000237	0.00303	CbGpPWpGaD
Glipizide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000234	0.00299	CbGpPWpGaD
Glipizide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000234	0.00299	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CYP24A1—multiple sclerosis	0.000233	0.00298	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CYP27B1—multiple sclerosis	0.000233	0.00298	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—HNRNPA1—multiple sclerosis	0.000231	0.00295	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—U2AF2—multiple sclerosis	0.000231	0.00295	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CYP24A1—multiple sclerosis	0.000226	0.00289	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CYP27B1—multiple sclerosis	0.000226	0.00289	CbGpPWpGaD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—multiple sclerosis	0.000225	0.00287	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—GPC5—multiple sclerosis	0.000213	0.00272	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—PGR—multiple sclerosis	0.000209	0.00267	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—GPC5—multiple sclerosis	0.000207	0.00264	CbGpPWpGaD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000188	0.0024	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—PTPRC—multiple sclerosis	0.000188	0.00239	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—ZFP36L1—multiple sclerosis	0.000183	0.00233	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—RRM1—multiple sclerosis	0.000177	0.00226	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—RRM1—multiple sclerosis	0.000172	0.00219	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—STAT3—multiple sclerosis	0.000171	0.00218	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CYP27B1—multiple sclerosis	0.000167	0.00213	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CYP24A1—multiple sclerosis	0.000167	0.00213	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000163	0.00208	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—TGFB1—multiple sclerosis	0.000159	0.00202	CbGpPWpGaD
Glipizide—PPARG—Metabolism—GPC5—multiple sclerosis	0.000153	0.00195	CbGpPWpGaD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000153	0.00194	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—TNF—multiple sclerosis	0.000148	0.00189	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—VDR—multiple sclerosis	0.000146	0.00186	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PABPC1—multiple sclerosis	0.000142	0.00181	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000138	0.00176	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000138	0.00176	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—RPL5—multiple sclerosis	0.000128	0.00163	CbGpPWpGaD
Glipizide—PPARG—Metabolism—RRM1—multiple sclerosis	0.000127	0.00162	CbGpPWpGaD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000124	0.00158	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—IL6—multiple sclerosis	0.00012	0.00152	CbGpPWpGaD
Glipizide—ABCC8—Neuronal System—MAPK1—multiple sclerosis	0.000118	0.0015	CbGpPWpGaD
Glipizide—KCNJ11—Neuronal System—MAPK1—multiple sclerosis	0.000114	0.00146	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000102	0.0013	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—BCHE—multiple sclerosis	0.000102	0.0013	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PGR—multiple sclerosis	0.000101	0.00128	CbGpPWpGaD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000101	0.00128	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—BCHE—multiple sclerosis	9.85e-05	0.00126	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.83e-05	0.00125	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—SRM—multiple sclerosis	8.74e-05	0.00111	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.45e-05	0.00108	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—IL6—multiple sclerosis	8.44e-05	0.00108	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—TYK2—multiple sclerosis	8.4e-05	0.00107	CbGpPWpGaD
Glipizide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	8.1e-05	0.00103	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.7e-05	0.000982	CbGpPWpGaD
Glipizide—PPARG—Metabolism—BCHE—multiple sclerosis	7.28e-05	0.000928	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—VDR—multiple sclerosis	7.04e-05	0.000897	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MMP9—multiple sclerosis	6.62e-05	0.000844	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	6.16e-05	0.000785	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	6.16e-05	0.000785	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—APOE—multiple sclerosis	6.11e-05	0.000779	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.02e-05	0.000768	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—APOE—multiple sclerosis	5.93e-05	0.000756	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—STAT3—multiple sclerosis	5.89e-05	0.00075	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—MYC—multiple sclerosis	5.81e-05	0.000741	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—SRM—multiple sclerosis	5.77e-05	0.000735	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—GPC5—multiple sclerosis	5.63e-05	0.000718	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—TGFB1—multiple sclerosis	5.46e-05	0.000695	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MAPK1—multiple sclerosis	5.35e-05	0.000682	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.34e-05	0.000681	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—POMC—multiple sclerosis	5.25e-05	0.000669	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—TNF—multiple sclerosis	5.09e-05	0.000649	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—POMC—multiple sclerosis	5.09e-05	0.000649	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ALB—multiple sclerosis	4.79e-05	0.00061	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—RRM1—multiple sclerosis	4.67e-05	0.000595	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ALB—multiple sclerosis	4.64e-05	0.000592	CbGpPWpGaD
Glipizide—PPARG—Metabolism—APOE—multiple sclerosis	4.38e-05	0.000558	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—IL6—multiple sclerosis	4.11e-05	0.000524	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.06e-05	0.000518	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.06e-05	0.000518	CbGpPWpGaD
Glipizide—PPARG—Metabolism—POMC—multiple sclerosis	3.76e-05	0.00048	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.72e-05	0.000474	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.62e-05	0.000462	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ALB—multiple sclerosis	3.43e-05	0.000437	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.11e-05	0.000397	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.08e-05	0.000393	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.84e-05	0.000362	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—MYC—multiple sclerosis	2.8e-05	0.000357	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—BCHE—multiple sclerosis	2.68e-05	0.000342	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.77e-05	0.000225	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—APOE—multiple sclerosis	1.61e-05	0.000206	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—POMC—multiple sclerosis	1.39e-05	0.000177	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ALB—multiple sclerosis	1.26e-05	0.000161	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—APOE—multiple sclerosis	1.06e-05	0.000136	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—POMC—multiple sclerosis	9.14e-06	0.000117	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ALB—multiple sclerosis	8.33e-06	0.000106	CbGpPWpGaD
